Skip to content
Search

Latest Stories

Submit Guest Post

ArcelorMittal’s Indian joint venture to commission project by 2026

Lakshmi Mittal says the expansion at Hazira plant in Gujarat is moving fast

ARCELORMITTAL executive chairman Lakshmi N Mittal has said his company’s Indian joint venture with Nippon Steel will commission its facility in Gujarat in three years.

ArcelorMittal Nippon Steel (AMNS) India, formed in 2019 following the acquisition of Essar Steel, is scaling up the capacity of its integrated flat steel plant at Hazira to 15 million tonnes. The joint venture is investing Rs 600 billion (£5.9 bn) in the project.

Mittal said the expansion work at the facility was moving at a fast pace with more than 20,000 people involved in the project construction.

"We have full confidence that with the cooperation of the centre (union government) and Gujarat government, we will be able to commission the project by 2026,” he said at the 20th year celebrations of the biannual investor summit Vibrant Gujarat in Ahmedabad on Wednesday (27).

"It is our target to double our production capacity in the first phase and then triple...we will also make advanced products for technology," Mittal told PTI.

He said once the project became operational, it would contribute to India’s self-reliance efforts by reducing the country’s steel imports.

The tycoon said the success of the G20 summit in New Delhi enhanced India’s image as a global consensus builder.

He said Gujarat, which had industries in sectors like automobile, electric vehicles, green hydrogen and semiconductors, provided reliable infrastructure and a stable policy environment.

In June, AMNS India announced a collaboration with the French digital automation and energy management firm Schneider Electric on the design of high-tech training facilities and programmes in ”smart manufacturing”.

Add EasternEye As Your Trusted Source
preferred source on google news

More For You

AstraZeneca

AstraZeneca chief executive Pascal Soriot says the company has the science, pipeline and team to deliver its long-term growth ambitions

Getty Images

AstraZeneca targets $80bn revenue by 2030 with $1.5bn savings and pipeline investment

  • AstraZeneca expects its restructuring programme to generate $1.5bn in annualised savings by 2029, with most of the money reinvested in research and development.
  • The plan could incur up to $2bn in one-off restructuring costs, although the company expects its overall workforce to continue growing.
  • Third-quarter revenue rose 7 per cent to $16.21bn, while oncology sales increased 17 per cent to $7.77bn.

AstraZeneca has unveiled plans to generate around $1.5bn in annual savings through a three-year restructuring programme, as chief executive Pascal Soriot shifts the focus back to growth and investment in its drug pipeline.

The British-based pharmaceutical group said its Reshaping for Sustainable Growth programme would redirect resources towards research and development, particularly its pipeline of more than 180 projects and emerging technologies.

Keep ReadingShow less